The 71st Annual Meeting of the Japanese Cancer Association − Towards a new era and liaison of cancer research and life science −

Program

Program

The 71st Annual Meeting of the Japanese Cancer Association
-Towards a new era and liaison of cancer research and life science-

Program at a Glance

  • Show Full Program
  • Collapse Program

Plenary Lecture

Plenary lecture 1

Wednesday, September 19, 1:00 PM

Chairperson: Naoyuki Taniguchi, RIKEN
Speaker: Kazuhiro Nagata, Kyoto Sangyo University
Stress responses and cellular homeostasis
Collapse

Plenary lecture 2

Thursday, September 20, 1:00 PM

Chairperson: Hiroshi Shiku, Mie University
Speaker: James P. Allison, Memorial Sloan-Kettering Cancer Center
Beyond Immune Checkpoint Blockade: Manipulation of T cell regulatory circuits in Cancer Therapy
Collapse

Special Program

How to promote the merits of cancer research in Japan

Thursday, September 20, 2:00PM

Chairpersons: Ryuzo Ueda, Aichi Medical University
Tetsuo Noda, The Cancer Institute of JFCR
Speakers: Morito Monden, The Cancer Control Promotion Council
Tomomitsu Hotta, National Cancer Center
Shinsuke Amano, Group Nexus Japan
Yusuke Nakamura, scientist, The University of Chicago / The University of Tokyo
Naoko Okamura, Ministry of Education, Culture, Sports, Science and Technology
Hirotsugu Kimura, Ministry of Health, Labour and Welfare
Collapse

Panel Discussion
(JCA-Japanese Society of Clinical Oncology Joint Program)

Current Status and Future Prospects of Translational Research in Japan

Friday, September 21, 9:00AM

Chairpersons: Kiyotaka Kuzushima, Aichi Cancer Center
  Yutaka Kohgo, Asahikawa Medical University
Speakers: Kenichi Tamiya, Ministry of Health, Labour and Welfare
  Shinichi Kageyama, Mie University
Academia-based activities of translational research
  Toshiyuki Sakai, Kyoto Prefectural University of Medicine
The strategy from finding seeds to TR.
  Shiro Akinaga, Kyowa Hakko Kirin Co., Ltd.
Status of Japan-initiated translational research: A view from a Japanese Pharmaceutical Company
  Koichi Fukino, Novartis Pharma K.K.
Translational Research in Japan; from the view points of the global pharmaceutical company
  Nishiyama Masahiko, Saitama Medical University
Translational Research Network in Asia as a Possible Approach to Future Development Study on Cancer Therapeutics
Collapse

JCA-AACR Joint Symposium

Advancement of cancer immunology and immunotherapy

Thursday, September 20, 9:00 AM

Chairpersons: Yutaka Kawakami, Keio University
James P. Allison, Memorial Sloan Kettering Cancer Center
Speakers: Toshihiko Torigoe, Sapporo Medical University
Immunopathological properties of cancer stem cells and application to cancer immunotherapy
Carl H.June, University of Pennsylvania
CAR T cells for leukemia and more?
Glenn Dranoff, Dana-Farber Cancer Institute
Mechanisms of Protective Tumor Immunity
Shinichi Hashimoto, Kanazawa University
Genome-wide single cell transcriptome and methylome methods for improvement of cancer immunotherapy
Yutaka Kawakami, Keio University
Multiple immunosuppressive cascades induced by cancer cells and their control by signal inhibitors
Collapse

Core Symposium

1. Projection from basic biology to cancer research

Wednesday, September 19, 2:00 PM

Chairpersons: Noriyuki Sato, Sapporo Medical University
  Stuart Calderwood, Beth Israel Deaconess Medical Center
Speakers: Stuart Calderwood, Beth Israel Deaconess Medical Center
Transcriptional Regulation of Molecular Chaperones in cell stress and cancer
  Kazutoshi Mori, Kyoto University
The unfolded protein response and cancer
  Tohru Nakano, Osaka University
DNA methylation in development and transformation
  Yoshinori Watanabe, The University of Tokyo
Chromosomal instability in cancer cells is caused by shugoshin dysfunction
  Masanori Hatakeyama, The University of Tokyo
Role of Helicobacter pylori CagA oncoprotein in gastric carcinogenesis
Collapse

2. New paradigm developed by next-generation sequencer

Thursday, September 20, 2:00 PM

Chairpersons: Hiroyuki Aburatani, The University of Tokyo
  Tatsuhiro Shibata, National Cancer Center Research Institute
Speakers: Hiroyuki Aburatani, RCAST, The University of Tokyo
Genomics of cancer progression
  Mamoru Kato, Cold Spring Harbor Laboratory
Evolutionary analysis of single-cell sequencing data to detect natural selection in tumor cells
  McDermott Ultan, Cancer Genome Project, Wellcome Trust Sanger
The genomics of drug sensitivity in cancer.
  Tatsuhiro Shibata, National Cancer Center Research Institute
Cancer transcriptome sequencing
  Seishi Ogawa, The University of Tokyo Hospital Cancer Board
Novel pathway mutations in myelodysplasia as revealed by whole genome/exome sequencing
  Jeffrey S. Ross, Department of Pathology and Laboratory Medicine Albany Medical College
Next-Generation Pathology: Deep DNA Sequencing and Targeted Therapy for Cancer
Collapse

3. Integration of developmental biology and cancer

Thursday, September 20, 9:00 AM

Chairpersons: Tetsuo Noda, The Cancer Institute of JFCR
  Masahide Takahashi, Nagoya University
Speakers: Masahide Takahashi, Nagoya University
Roles of AKT substrate Girdin in cancer progression and angiogenesis
  Kwok Kin Wong, Dana Farber Cancer Institute
Mouse Models of Lung Cancer Progression
  Makoto Mark Taketo, Kyoto University
Metastasis suppressor gene AES/Aes is an endogenous Notch signaling inhibitor
  Akira Suzuki, Kyushu University
Functional analysis of tumor suppressor genes Mob1A/1B
  Takuro Nakamura, The Cancer Institute of JFCR
Oncogenic stimuli and tumor origin
Collapse

4. Scientific progress of human tumor immunology

Wednesday, September 19, 9:00 AM

Chairpersons: Kohzoh Imai, The University of Tokyo
  Yusuke Nakamura, The University of Tokyo
Speakers: Yusuke Nakamura, The University of Tokyo
Development of therapeutic cancer peptide vaccine and construction of translational research network
  Yasuharu Nishimura, Kumamoto University
Efficient induction of tumor immunity by the ideal TAA-derived peptides carrying both CTL and Th1 cell epitopes
  Kouji Matsushima, The University of Tokyo
Alleviation of GVHD by anti-CD4 antibody preserving GVL/T effect in allo-HSCT
  Francesco M Marincola, National Institutes of Health
Common signatures of rejection
Collapse

5. Molecular pathology of cancer stem cell/cancer initiating cell

Friday, September 21, 9:00 AM

Chairpersons: Kohei Miyazono, The University of Tokyo
  Toshio Suda, Keio University
Speakers: Kohei Miyazono, The University of Tokyo
Regulation of cancer-initiating cell function by TGF-beta
  Koichi Akashi, Kyushu University
Pathogenesis of Cancer Stem Cells in Human Hematological Malignancies
  Keiyo Takubo, Keio University
Regulation of leukemia initiating cells in the hypoxic niche
  Daniel G. Tenen, Cancer Science Institute of Singapore, NUS
Regulation of myeloid transcription factors and DNA methylation by noncoding RNAs
Collapse

International Sessions

1. Translational gastric cancer research

Wednesday, September 19, 9:00 AM

Chairpersons: Masahiro Asaka, Hokkaido University
  Khay-Guan Yeoh, National University of Singapore
Speakers: Toshikazu Ushijima, National Cancer Center Research Institute
Bringing Epigenetic Field Defect into Cancer Risk Diagnosis and Prevention
  Li-Ling Lin, National Taiwan University
Annexin A4, a gastric cancer marker, triggers a signaling cascade for cell proli feration
  Patrick Tan, Genome Institute of Singapore
Dissecting Gastric Cancer Heterogeneity : Genomic Approaches and Clinical Impact
  Sun Young Rha, Yonsei Cancer Center, Yonsei University
Strategic approach of new drug development in gastric cancer
  Mitsuru Kaise, Toranomon Hospital
Advances in endoscopic diagnosis and treatment for gastric cancer
  Khay-Guan Yeoh, National University of Singapore
Early detection of gastric cancer: Predicting high risk groups
  Mototsugu Kato, Hokkaido University Hospital
Strategy for elimination of gastric cancer in Japan
Collapse

2. Perspective of molecular epidemiologic cohort in Asia

Wednesday, September 19, 9:00 AM

Chairpersons: Keitaro Matsuo, Aichi Cancer Center Research Institute
  Daehee Kang, Seoul National University
Speakers: Daehee Kang, Seoul National University
Evolution of Cohort Studies in Asia
  Motoki Iwasaki, National Cancer Center
Current status of molecular epidemiologic cohort study in National Cancer Center, Japan
  Kenji Wakai, Nagoya University Graduate School of Medicine
The Japan Multi-institutional Collaborative Cohort (J-MICC) Study: its achievement and perspectives
  Hidemi Ito, Aichi Cancer Center Research Institute
Potential of the Hospital based Epidemiologic Research Program at Aichi Cancer Center as a genome cohort study
  Woon-Puay Koh, National University of Singapore
Gene-environment interactions and cancer risk: findings from The Singapore Chinese Health Study
  Minkyo Song, Seoul National University, College of Medicine
Profiles of the Health Examinees Study using Biomarker in Korean Population: An Interim Report
  Fang-Hui Zhao, Cancer Institute/Hospital,Chinese Academy of Medical Sciences
Effectiveness and Health Economic Analysis of Strategies on Cervical Cancer Screening and Early Diagnosis and Treatment
Collapse

3. Tumor angiogenesis

Friday, September 21, 2:00 PM

Chairpersons: Kyoko Hida, Hokkaido University
  Gou Young Koh, Korea Advanced Institute Science and Technology (KAIST)
Speakers: Gou Young Koh, Korea Advanced Institute Science and Technology (KAIST)
Role of VEGF-A and Angiopoietins in Tumor Angiogenesis and Vessel Destabilization
  Yasufumi Sato, Tohoku University
The role of vasohibin family in cancers
  Tetsuro Watabe, University of Tokyo
Roles of signaling and transcriptional networks during TGF-beta-induced endothelial-to-mesenchymal transition (EndMT)
  Young-Guen Kwon, Yonsei University, Korea
Promotion of vascular integrity resulted in normalization of tumor blood vessels
  Kyoko Hida, Hokkaido University
Crosstalk between tumor endothelial cells and tumor cells.
  Nobuyuki Takakura, Osaka University
Requirement for perivascular niche for maintenance of cancer stem cells
Collapse

4. Development of new anticancer drugs in Asia

Friday, September 21, 2:00 PM

Chairpersons: Atsushi Ohtsu, National Cancer Center
  Hyun Cheol Chung, Yonsei University
Speakers: Huei-Wen Chen, National Taiwan University Medical College
Hinokitiol inhibits gefitinib-resistant lung adenocarcinoma cancer cell prolifer ation through G2/M arrest
  Toshihiko Doi, National Cancer Center Hospital East
Development of new anticancer drugs in Asia: early clinical trials in c-MET/HGF signal inhibitors
  Hyun Cheol Chung, Yonsei University
Early clinical trial of anti-angiogenesis agents for BAD determination
  Eng-Huat Tan, National Cancer Centre, Singapore
Drug development in Lung Cancer in Asia
  Kenji Tamura, National Cancer Center Hospital
Development of new anti-cancer drugs in the field of breast cancer in Asia
  Winnie Yeo, Chinese University of Hong Kong
Epigenetic Therapy in Liver Cancer
  Takayuki Yoshino, National Cancer Center Hopital East
Update on Promising New Agents for Unresectable Metastatic Colorectal Cancer
  Sumimasa Nagai, Pharmaceuticals and Medical Devices Agency
The comparison of review process of drugs for hematological malignancies by the PMDA with the FDA
Collapse

5. Molecular targets for cancer therapy

Thursday, September 20, 2:00 PM

Chairpersons: Hiroyuki Seimiya, JFCR Cancer Chemotherapy Center
  In-Hoo Kim, National Cancer Center
Speakers: In-Hoo Kim, National Cancer Center
Development and application of aptamer-antibody hybrid complex as an efficient targeting agent
  Hiroyuki Seimiya, JFCR Cancer Chemotherapy Center
Targeting glioma stem cells by G-quadruplex ligands
  Siu Tim Cheung, The University of Hong Kong
Genomic approach identified growth factor GEP and ABC transporters associated with HCC recurrence and chemoresistance
  Tomohiro Fujiwara, National Cancer Center Research Institute
A Novel Therapeutic Strategy against Tumor-initiating Cells of Osteosarcoma: microRNA Inhibition with Current Treatment
  Yon Hui S. Kim, National Cancer Center, Korea
Multi-layer integrative analysis of the whole transcriptome in Asian gastric cancer
  Seiji Yano, Cancer Research Institute, Kanazawa University
Ligand-stimulated receptor activation as novel targets to overcome resistance to molecular targeted drugs in lung cancer
  Ryohei Katayama, MGH Cancer Center/Harvard Medical School
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers
Collapse

6. Inflammation and cancer

Thursday, September 20, 9:00 AM

Chairpersons: Masanobu Oshima, Kanazawa University
  Young-Joon Surh, Seoul National University
Speakers: Masanobu Oshima, Kanazawa University
Inflammation and Cancer
  Hye-Kyung Na, Sungshin Women's University, Seoul, Korea
15-Hydroxyprostaglandin Dehydrogenase as a Novel Target for Chemoprevention of Inflammation-Associated Carcinogenesis
  Akira Kikuchi, Osaka University
Wnt as a common mediater for inflammation and tumorigenesis
  Brendan J. Jenkins, Monash University
Novel role for TLR2 promoting tumorigenesis independent of inflammation in gastric cancer
  Yoshiro Maru, Tokyo Women's Medical University
An interface between metastasis and inflammation
  Junichiro Inoue, The University of Tokyo
Critical roles of NF-kB activation in breast cancer development
  Young-Joon Surh, Seoul National University
Modulation of Pro-inflammatory and Anti- inflammatory Signaling for Cancer Chemoprevention and Treatment
Collapse

7. Cancer nanomedicine

Thursday, September 20, 2:00 PM

Chairpersons: Yasuhiro Matsumura, National Cancer Center Hospital East
  Wu-Chou Su, National Cheng Kung University
Speakers: Tetsuya Hamaguchi, National Cancer Center Hospital
Clinical studies of polymer micelles incorporating anticancer agents
  Wu-Chou Su, National Cheng Kung University
The development of nanodevices engineered to suppress IL-6/Jak/Stat3 pathway to improve cancer treatment
  Hidetaka Akita, Hokkaido University
Development of the nanoparticle for DNA vaccine based on the control of intracellular trafficking and signaling
  Maggie Lu, ITRI
The nanomedicine approach for treating glioblastoma
  Yi-Yan Yang, Institute of Bioengineering and Nanotechnology, Singapore
Micelles Self-Assembled from Polycarbonate-PEG Block Copolymers for Anticancer Drug Delivery
  Nobuhiro Nishiyama, The University of Tokyo
Design of polymeric micelles for the targeting of intractable cancers.
Collapse

8. Cancer genome sequencing and how to interpret mutation data

Thursday, September 20, 9:00 AM

Chairpersons: Hidewaki Nakagawa, Center for Genomic Medicine, RIKEN
  Jun Wang, Beijing Genomics Institute (BGI)
Speakers: Akihiro Fujimoto, Center for Genomic Medicine, RIKEN
Whole genome sequence and comprehensive data analysis of cancer genome
  Masashi Sanada, The University of Tokyo
Novel pathway mutations in myelodysplasia revealed by high throughput sequencing technology
  Niranjan Nagarajan, Genome Institute of Singapore
Landscape of Somatic Alterations and their Functional Consequences in Gastric Cancer
  Ren Shancheng, Shanghai Changhai Hospital
RNA-seq analysis of Chinese prostate cancer identifies recurrent gene fusions, cancer-associated long noncoding RNAs
  Jun Wang, Beijing Genomics Institute (BGI)
Genetic Analysis of three Cancers and Cancer Progression Using Single-Cell Sequencing
Collapse

9. Molecular imaging in cancer research and treatment

Wednesday, September 19, 2:00 PM

Chairpersons: Masahiro Hiraoka, Kyoto University
  June-Key Chung, Seoul National University Hospital
Speakers: June-Key Chung, Seoul National University Hospital
Introduction of molecular imaging
  Arifudin Achmad, Gunma University
A Preliminary Report on HER1-targeted PLGA-PEG Nanobubbles as an Intratumor-specific targeted Ultrasound Contrast Agent
  Keon Wook Kang, Seoul National University College of Medicine
in vivo Nano-Molecular Imaging of Cancer
  Hiroshi Harada, Kyoto University
Cancer cells that acquire HIF-1 activity after radiotherapy cause local tumor recurrence; An optical imaging research
  Koichi Yasuda, Hokkaido University Graduate School of Medicine
Hypoxia imaging and Radiation therapy
Collapse

10. Basic and clinical advances in cancer epigenetics research

Friday, September 21, 9:00 AM

Chairpersons: Hiromu Suzuki, Sapporo Medical University
  Mingzhou Guo, Chinese PLA General Hospital
Speakers: Keiko Shinjo, Aichi Cancer Center Research Institute
Clinical implications of epigenetic markers in thoracic malignancies
  Joo Mi Yi, Dongnam Institute of Radiological & Medical Sciences (DIRAMS)
Clinical Application of DNA Hypermethylome in Colon Cancer
  Hiromu Suzuki, Sapporo Medical University
Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors
  Mingzhou Guo, Chinese PLA General Hospital
Methylation of DACT2 Activated WNT Signaling Pathway in human Lung and GI Cancer
  Sung-Liang Yu, National Taiwan University
DNA methylation involved in chemotherapeutic efficacy in lung cancer
  Katsuya Ohta, Osaka University
Epigenetic Regulation Modulates Biological Behaviors of Colon Cancer Stem Cells
Collapse

11. Maintaining the integrity of genomic information by cell cycle checkpoints

Friday, September 21, 9:00 AM

Chairpersons: Makoto Nakanishi, Nagoya City University
  Hyeseong Cho, Ajou University
Speakers: Hyeseong Cho, Ajou University
Mitotic Regulation of Rsf-1, a Subunit of Remodeling and Spacing Factor Complex
  Randy Poon, The Hong Kong University of Science and Technology
Mitotic catastrophe: mechanisms and therapeutic potential
  Yoshikazu Johmura, Nagoya City University
Senescent cells are tetraploid G1 cells generated by mitotic skipping
  Richard W. Wong, Kanazawa University
The role of Nuclear Pore Proteins in coordination of cell cycle checkpoints during mitosis
  Junya Unno, Kyoto University
Crosstalk signaling between checkpoint and the Fanconi anemia DNA repair pathway
  Akimitsu Konishi, Tokyo Medical and Dental University
Checkpoint recovery from DNA damage
  Hong-Duk Youn, Seoul National University College of Medicine
Cell cycle regulation by OGFOD1 in breast cancer cells
Collapse

12. Health care economics – The significance of UN-Summit NCDs political declaration in Asia (UICC International Session)

Wednesday, September 19, 2:00 PM

Chairpersons: Hideyuki Akaza, University of Tokyo
  Jae Kyung Roh, Yonsei University
Speakers: Norie Kawahara, The University of Tokyo
Promoting perceptions of cancer as an integral part of the global health agenda
  Eun-Cheol Park, Yonsei University
The economic burden of cancer in Korea
  Hajime Inoue, Chiba Prefecture
Japan's role for controlling Non Communicable Diseases (NCDs) in Asia
  Keizo Takemi, Tokai University
Political issue for realizing the declaration in the World
  Shinjiro Nozaki, The Global Health Workforce Alliance, WHO Geneva
Health Workforce Crisis in the World
  Ludwig Kanzler, McKinsey & Company, Inc., Japan
Innovative Financing of Cancer Care in Asia
  Masafumi Nogimori, Astellas Pharma Inc.
Pharmaceutical industry’s contribution to the prevention and control of NCDs in accordance with the UN political declaration
  Pascal Rigaudy, sanofi-aventis K.K
Oncology in Asian Countries: Clinical Development Challenges and Opportunities
  Jae Kyung Roh, Yonsei University
Post Presentation Discussion; Health Care Economics - The Significance of UN-Summit NCDs Political Declaration in Asia
Collapse

Symposium

1. Recent development of chromosome and genome instability research

Wednesday, September 19, 9:00 AM

Chairpersons: Fuyuki Ishikawa, Kyoto University
  Johji Inazawa, Tokyo Medical and Dental University
Speakers: Fuyuki Ishikawa, Kyoto University
Telomere dysfunctions and chromosome instability
  Noriko Hosoya, The University of Tokyo
The role for a meiosis-specific protein in regulating DNA damage response and chromosome stability in cancer
  Johji Inazawa, Tokyo Medical and Dental University
Mechanisms for complex rearrangements in human genome
  Yuichi Ishikawa, Cancer Institute of JFCR
Chromosome and genome instability in lung and kidney tumors
  Hidewaki Nakagawa, RIKEN Center for Genomic Medicine
Whole genome sequencing analysis of cancer
Collapse

2. Recent progress of non-coding RNA and cancer

Thursday, September 20, 2:00 PM

Chairpersons: Hidetoshi Tahara, Hiroshima University
  Masatoshi Kitagawa, Hamamatsu University
Speakers: Hidetoshi Tahara, Hiroshima University
Micromanagement of cancer by senescence-associated micro RNA
  Hiroshi Suzuki, The University of Tokyo
Complexity of microRNA biogenesis and inference of small RNA network through transcriptome analysis
  Gregory J. Goodall, Centre for Cancer Biology, SA Pathology
UV-Crosslink Immunoprecipitation (HITS-CLIP) identifies regulatory networks targeted by the miR-200 family of microRNAs
  Ryouu Takahashi, National Cancer Center Research Institute
Identification of microRNA-27b as a master regulator generating breast cancer stem cells
  Ken-ichi Kozaki, Tokyo Med. & Dent. Univ
Methylation-based screening of tumor-suppressive microRNAs in cancer cells
  Tatsuya Ohhata, Hamamatsu University
Recent progress of long non-coding RNA research
  Riki Kurokawa, Saitama Medical University
Long noncoding RNA as an epigenetic regulatory factor
Collapse

3. Recent progress of epigenetics and cancer biology

Wednesday, September 19, 2:00 PM

Chairpersons: Toshikazu Ushijima, National Cancer Center Research Institute
  Yutaka Kondo, Aichi Cancer Center Research Institute
Speakers: Yutaka Kondo, Aichi Cancer Center Research Institute
Epigenetic modifiers and non-coding RNA in plastic cancer stem-like cells and their therapeutic implications
  Satoshi Fujii, National Cancer Center Research Institute
Histone adaptation of cancer cell
  Hideo Iba, The University of Tokyo
A SWI/SNF complex catalytic subunit, Brm, as a key epigenetical regulator in cancer cells
  Atsushi Kaneda, The University of Tokyo
Cancer epigenotypes and tumor development mechanisms
  Ajay Goel, Baylor University Medical Center
Epigenetics of Colorectal Cancer
  Koji Hase, The University of Tokyo
Intestinal microbiota shapes intestinal T cell balance via epigenetic modifications
Collapse

4. Molecular targeting to cancer stem cell/cancer initiating cell

Wednesday, September 19, 9:00 AM

Chairpersons: Masaki Mori, Osaka University
  Toshihiko Torigoe, Sapporo Medical University
Speakers: Yoshihiko Hirohashi, Sapporo Medical University
Cancer Immunotherapy targeting to cancer stem cell/cancer initiating cell
  Naotsugu Haraguchi, Osaka University
Cellular properties of cancer stem cells in gastroenterological cancer
  Hideyuki Saya, Keio University
A novel therapeutic approach targeting the CD44 variant functions
  Takahiro Ochiya, National Cancer Center Research Institute
Micromanaging cancer stem cells by targeting ribophorin II
  Noriko Gotoh, The University of Tokyo
Growth factor receptor signaling controls breast cancer stem cells and their niche
  Shinji Tanaka, Tokyo Medical and Dental University
Real-time imaging of pancreatic cancer stem cells to identify the selectively targeting therapy
Collapse

5. New aspect of cell cycle research and cancer

Wednesday, September 19, 2:00 PM

Chairpersons: Keiichi Nakayama, Kyushu University
  Eiji Hara, The Cancer Institute of JFCR
Speakers: Eiji Hara, The Cancer Institute of JFCR
The roles and mechanisms regulating cellular senescence in cancer
  Keiichi Nakayama, Kyushu University
Deciphering mechanism underlying G0 maintenance: Can we eradicate cancer stem cell?
  Makoto Nakanishi, Nagoya City University
Inheritance of epigenetic information during DNA replication through a Uhrf1-Dnmt1 axis and replication machineries
  Tatsuo Fukagawa, National Institute of Genetics
Kinetochore structure, which ensures for accurate chromosome segregation
  Philipp Kaldis, Institute of Molecular and Cell Biology (IMCB)
Cdk1 is essential for cell division, suppression of DNA rereplication and tumor formation but not for liver regeneration
  Yoshinori Kagawa, Osaka University
A novel cell cycle-associated RhoGAP, Celmobilin, regulates cancer cell motility and invasion in human.
Collapse

6. Signal transduction and cancer therapy

Friday, September 21, 9:00 AM

Chairpersons: Hidenori Ichijo, The University of Tokyo
  Akinori Takaoka, Hokkaido University
Speakers: Miki Kamiyama, The University of Tokyo
ASK family-dependent stress signaling in tumor progression
  Mutsuhiro Takekawa, The University of Tokyo
A novel role of the stress-responsive MAPK pathways in preventing centrosome amplification and its failure in cancer
  Nobuyuki Tanaka, Nippon Medical School
Role of enhanced glycolysis in oncogenic transformation in culture cells and tumor development.
  Toru Kondo, Hokkaido University
Analysis of signaling pathways that are involved in the maintenance of glioma-initiating cells.
  Masao Saito, University of Yamanashi
Roles of TGF-β superfamily signals in EMT and cancer progression
  Tomohiko Tamura, Yokohama City University
The transcription factor IRF8 in the pathogenesis and therapy of chronic myelogenous leukemia
Collapse

7. p53 family and cancer research

Wednesday, September 19, 9:00 AM

Chairpersons: Takashi Tokino, Sapporo Medical University
  Akira Nakagawara, Chiba Cancer Center
Speakers: Koichi Matsuda, The University of Tokyo
Regulation of histone modification and chromatin structure by the p53-PADI4 pathway
  Masato Enari, National Cancer Center Research Institute
p53 inactivation by anaplastic lymphoma kinase through tyrosine phosphorylation of p53
  Rieko Ohki, National Cancer Center Research Institute
PH domain-only protein PHLDA3; a p53-regulated repressor of Akt and a novel tumor suppressor of endocrine tumors
  Yasushi Sasaki, Sapporo Medical University
p53 family network and tumor suppression
  Kanaga Sabapathy, National Cancer Centre Singapore
Expected and unexpected roles of the p53 family member, p73, in regulating carcinogenesis
  Yusuke Suenaga, Chiba Cancer Center Research Institute
Functional roles of TAp63 and Myc in neural cancers
Collapse

8. Autophagy, proteostasis and cancer research

Wednesday, September 19, 2:00 PM

Chairpersons: Hirofumi Arakawa, National Cancer Center Research Institute
  Shigetsugu Hatakeyama, Hokkaido University
Speakers: Shigetsugu Hatakeyama, Hokkaido University
TRIM proteins and cancers
  Tomohiko Ohta, Marianna University
DNA replication and checkpoint regulated by HERC2 and BRCA1 E3 ubiquitin ligases
  Shigeomi Shimizu, Tokyo Medical and Dental University
Alternative macroautophagy and cancer
  Shinji Saiki, Juntendo University
Present status of development of cancer medicines targeting autophagy
  Alan Yueh-Luen Lee, National Health Research Institutes
Overexpression of mitochondrial Lon protease contributes malignant tumor progression
  Jun Inoue, Tokyo Med. & Dent. Univ
Gene aberration of autophagy-related genes in human cancers
  Hirofumi Arakawa, National Cancer Research Institute
Mitochondrial quality control and cancer: Mieap, a p53-inducible protein, controls mitochondrial quality
Collapse

9. Cell competition and communication in cancer

Wednesday, September 19, 9:00 AM

Chairpersons: Yasuyuki Fujita, Hokkaido University
  Takashi Kojima, Sapporo Medical University
Speakers: Yasufumi Fujita, Hokkaido University
Interactions between normal and transformed epithelial cells- A road to a novel type of cancer prevention and treatment
  Tatsushi Igaki, Kobe University
Tumor growth regulation by cell competition
  Nobuyoshi Kosaka, National Cancer Center Research Institute
Competitive interactions of cancer cells and normal cells via secretory microRNAs
  Yasufumi Omori, Akita University
Recto-verso of connexin in cancer development and progression
  Makoto Asamoto, Nagoya City University
Roloes of connexin expression in carcinogenesis and cell death
Collapse

10. Molecular pathophysiology of tumor microenvironment

Thursday, September 20, 2:00 PM

Chairpersons: Motoharu Seiki, The University of Tokyo
  Atsushi Ochiai, National Cancer Center Hospital East
Speakers: Genichiro Ishii, National Cancer Center Hospital East
Pathobiological mechanism of tumor progression by cancer associated fibroblasts
  Akira Orimo, Juntendo University
Carcinoma-associated fibroblasts educate incipient human mammary carcinoma cells to become invasive and metastatic
  Masahiro Sonoshita, Kyoto University
Roles of Notch signaling in tumor microenvironment
  Naoya Fujita, The Cancer Institute of JFCR
Involvement of platelet-tumor interaction in tumor cell survival and metastasis
  Yuichi Oike, Kumamoto University
Role of Angiopoietin-like protein 2 in carcinogenesis and metastasis
  Takeharu Sakamoto, The University of Tokyo
Mint3 promotes tumor malignancy in cancer and stromal cells
  Xueying Sun, Harbin Medical University
Blocking Hypoxia-inducible pathways improves the efficacy of doxorubicin to treat hepatocellular carcinoma
Collapse

11. Molecular basis of tumor immunity enhancing

Thursday, September 20, 2:00 PM

Chairpersons: Tsukasa Seya, Hokkaido University
  Yasuaki Tamura, Sapporo Medical University
Speakers: Kensuke Miyake, The University of Tokyo
Molecular mechanisms linking TLR7 distribution with TLR7-dependent IFNalpha production in plasmacytoid dendritic cells
  Tsukasa Seya, Hokkaido University
A crucial RNA adjuvant for immunotherapy for cancer
  Tahiro Shin, Okaya City Hospital
Aging-associated B7-DC+ B cells enhance anti-tumor immunity
  Yasuaki Tamura, Sapporo Medical University
Heat shock proteins act as endogenous enhancers building a bridge between innate immunity and adaptive immunity
  Masato Tanaka, Tokyo University of Pharmacy and Life sciences
The role of CD169 macrophages in anti-tumor immunity
  Hideki Ueno, Baylor Institute for Immunology Research
Anti-tumor immunity induced by dendritic cell-based vaccine in cancer patients
  Hidetoshi Sumimoto, Teikyo University
BRAF-MAPK signal inhibits chemokine production; Implication of BRAF-targeted therapy for immunotherapy in melanoma
Collapse

12. Perspective of new generation immunotherapy

Friday, September 21, 2:00 PM

Chairpersons: Takashi Nishimura, Hokkaido University
  Kyogo Itoh, Kurume University
Speakers: Ryuzo Ueda, Aichi Medical University
Mogamulizumab is a promising new candidate of incorporated modulators for the cancer vaccine therapy
  Christoph H. Huber, TRON Institute, Mainz University Medical Centre, Germany
Exploiting the Mutanome for Tumor Vaccination
  Tetsuro Sasada, Kurume University
Personalized peptide vaccine: a novel treatment modality for advanced cancer
  Takashi Nishimura, Hokkaido University
Development of an innovative cancer vaccine, helper/killer-hybrid epitope long peptide(H/K-HELP)
  Hisashi Wada, Osaka University
NY-ESO-1 long peptide vaccine
Collapse

13. Live cell imaging and cancer research

Thursday, September 20, 9:00 AM

Chairpersons: Yasuteru Urano, The University of Tokyo
  Takeshi Imamura, Ehime University
Speakers: Shinae Kondoh, Tokyo Institute of Technology
Functional real-time imaging of the tumor microenvironment
  Seiji Tobita, Gunma University
Imaging of cellular oxygen levels and hypoxic tissues using iridium complex probes
  Hideo Higuchi, The University of Tokyo
In vivo imaging of tumor and blood cells with high spatiotemporal precision
  Norihiro Kokudo, The University of Tokyo
Liver cancer surgery guided by in vivo ICG fluorescence
  Hisataka Kobayashi, National Institutes of Health
Molecular cancer imaging; Cutting edge of the theranostic technology
  Koji Okamoto, National Cancer Center Research Institute
The functional screening method for metastasis-regulatory genes via combination of mouse models and fluorescent imaging
Collapse

14. Structural biology and cancer therapy

Thursday, September 20, 9:00 AM

Chairpersons: Osamu Nureki, The University of Tokyo
  Katsumi Maenaka, Hokkaido University
Speakers: Tatsuya Nishino, National Institute of Genetics
Structural cell biology of chromosome segregation machinery
  Kouhei Tsumoto, The University of Tokyo
Thermodynamic analysis of antibody-antigen interactions
  Shigeyuki Yokoyama, RIKEN
Structural studies on cancer-related signaling and epigenetic proteins
  Masayuki Yamamoto, Tohoku University
Molecular and Structural Basis of Keap1-Nrf2 System Function
  Kazumitsu Ueda, Kyoto University
Crystal structure of a MDR1-type ABC protein
  Osamu Nureki, The University of Tokyo
Structure of a dominant-negative helix-loop-helix transcriptional regulator suggests mechanisms of autoinhibition
  Katsumi Maenaka, Hokkaido University
Structural basis for HLA recognition of killer cell Ig-like receptors
Collapse

15. Concurrent integration of pathology and cancer research

Friday, September 21, 2:00 PM

Chairpersons: Shinya Tanaka, Hokkaido University
  Masashi Fukayama, The University of Tokyo
Speakers: Yoshinori Murakami, The University of Tokyo
Dual roles of a cell adhesion molecule, CADM1, in lung oncogenesis based on the molecular pathological analyses
  Makoto Sano, Nihon University
Activation of Wnt/β-catenin signaling pathway in KrasG12D-induced pancreatic cancer development
  Etsuko Kiyokawa, Kanazawa Medical University
Mechanisms for luminal cell filling detected by fluorescent live imaging
  Sug Hyung Lee, The Catholic University of Korea
Apoptosis and autophagy: combination of pathological and genetical approach.
  Masahiko Kuroda, Tokyo Medical University
Relationship between morphological structure and micro RNA signature during colon cancer development
  Shinya Tanaka, Hokkaido University
Molecular and pathological analysis of malignant glioma: from tissues to therapeutic reagents
  Shunpei Ishikawa, The University of Tokyo
Sequencing-based global analysis of cancer-microenvironment interactome
Collapse

16. Personalized cancer medicine and biomarker

Friday, September 21, 9:00 AM

Chairpersons: Yasuhisa Shinomura, Sapporo Medical University
  Kazuto Nishio, Kinki University
Speakers: Kiyoshi Yanagisawa, Nagoya University
Proteomic identification of potential biomarkers of malignant pulmonary mesothelioma
  Hiroyuki Yamamoto, Sapporo Medical University
Genetic alterations-based molecular diagnosis and personalized therapy of gastrointestinal cancer
  Takashi Kohno, National Cancer Center Research Institute
The KIF5B-RET fusion gene: Individualized therapy of lung adenocarcinoma based on somatic genetic alterations
  Tetsuya Nakatsura, National Cancer Center Hospital East
Potential of Cancer Immunotherapy for Personalized cancer medicine
  Kenji Yasuda, Tokyo Medical and Dental University
Development of on-chip imaging flow cytometry technology for circulating tumor cell analysis
  Yasuhiro Koh, Shizuoka Cancer Center Research Institute
Development of novel systems for the detection of circulating tumor cells in Japan
  Tomoko Yoshino, Tokyo University of Agriculture and Technology
Development of microcavity array system for isolation and detection of circulating tumor cells
Collapse

17. Diabetes and cancer (JCA-Japan Diabetes Society Joint Symposium)

Friday, September 21, 2:00 PM

Chairpersons: Masato Kasuga, National Center for Global Health and Medicine
  Hitoshi Nakagama, National Cancer Center Research Institute
Speakers: Manami Inoue, Research Center for Cancer Prevention and Screening, National Cancer Center
Diabetes and Cancer: Epidemiological Evidence
  Hiroshi Noto, National Center for Global Health and Medicine
Cancer risk in diabetic patients treated with metformin
  Mei-Shu Lai, National Taiwan University
Anti-diabetic drugs and cancer risk in type 2 diabetes mellitus patients
  Wataru Ogawa, Kobe University
Insulin resistance and pathogenesis of cancer
  Michihiro Mutoh, National Cancer Center Research Institute
Role of hypertriglyceridemia in diabetes-associated carcinogenesis
  Masahito Shimizu, Gifu University
Targeting obesity-and diabetes-related metabolic abnormalities for chemoprevention of hepatocellular carcinoma
  Kohjiro Ueki, Tokyo University
Possible mechanisms linking treatment for diabetes and cancer risk
Collapse

18. Challenging cancer research from international frontier

Friday, September 21, 9:00 AM

Chairpersons: Toshimitsu Uede, Hokkaido University
  Kazuo Tajima, Aichi Cancer Center Research Institute
Speakers: Lenan Shao, Department of Biomedical Engineering,Tohoku University
Lymphatic drainage routes mapping in a n ovel experimental lymph metastasis model of mice
  Motomi Osato, National University of Singapore
Runx family genes and tumorigenesis
  Shinichi Takayama, Boston Biomedical Research Institute
Pathophysiological role of molecular chaperones in cancer and muscle disease
  Kwan-Hwa Chi, Shin Kong Hospital
Modulation of Autophagy Pathway: Effective Combinations for Reversing Drug Resistance
  Naoto Hirano, University of Toronto
The reality of "first-in-human" clinical trials in cancer research: Artificial APC-based adoptive cell therapy
Collapse

19. Radiation carcinogenesis

Thursday, September 20, 9:00 AM

Chairpersons: Kiyoshi Miyagawa, The University of Tokyo
  Kenji Kamiya, Hiroshima University
Speakers: Kotaro Ozasa, Radiation Effects Research Foundation
Long-term radiation risk of cancer in the atomic-bomb survivors
  Kiyohiro Hamatani, Radiation Effects Research Foundation
Characteristics of early molecular events in radiation-associated adult-onset papillary thyroid carcinogenesis
  Ignacia Tanaka, Institute for Environmental Sciences
Neoplasia in Mice Exposed Chronically to Very Low Dose-Rates of Gamma Rays
  Ryo Kominami, Niigata University
Radiation target cells in thymic lymphomas
  Peter Wushou Chang, Taipei Medical University
Cancer risks from protracted low dose-rate ionizing radiation in a specific human population
  Sumitaka Hasegawa, Molecular Imaging Center, National Institute of Radiological Sciences
Radiation-induced mouse thymic lymphomagenesis is accelerated by overexpression of H-ferritin
Collapse

Symposium on Specific Tumors

1. Topics of lung cancer

Wednesday, September 19, 9:00AM

Chairpersons: Hirotoshi Akita, Hokkaido University
  Hiroyuki Mano, Jichi Medical University / The University of Tokyo
Speakers: Ichiro Kinoshita, Hokkaido University
Role of polycomb group protein EZH2 in lung cancer
  Tomoya Yamaguchi, Nagoya University
TTF-1-induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma
  Manabu Soda, Jichi Medical University
Targeting ALK-fusions in lung cancer
  Kengo Takeuchi, The Cancer Institute, Japanese Foundation for Cancer Research
Novel fusion kinases in lung cancer
  S. Tiong Ong, Duke-NUS Graduate Medical School, Singapore
A Novel BIM Polymorphism Linked to TKI Responses
Collapse

2. Topics of hematological malignancy

Wednesday, September 19, 2:00PM

Chairpersons: Yoshihiro Matsuno, Hokkaido University Hospital
  Masao Seto, Aichi Cancer Center
Speakers: Yoshikane Kikushige, Kyushu University
Self-Renewing Hematopoietic Stem Cell Is the Primary Target in Pathogenesis of Chronic Lymphocytic Leukemia
  Momoko Nishikori, Kyoto University
A murine model for elucidating the mechanism of lymphoma subtype determination
  Tadashi Yoshino, Okayama University
Histological findings and molecular pathology of the lymphoma
  Kunihiro Tsukasaki, Nagasaki University
Progress in the treatment of T-cell lymphoma
  Tomohiro Kinoshita, Aichi Cancer Center Hospital
Recent progress in treatment of B-cell lymphoma
Collapse

3. Topics of gastrointestinal cancer

Thursday, September 20, 9:00AM

Chairpersons: Koichi Hirata, Sapporo Medical University
  Yasuhiro Fujiwara, National Cancer Center Hospital
Speakers: Yuichiro Doki, Osaka University
Molecular biological characteristics of human esophageal cancers
  Tohru Niwa, National Cancer Center Research Institute
Alterations of a histone modification is possibly involved in an epigenetic field for cancerization
  Akira Sawaki, Nagoya Daini Red Cross Hospital
Epigenetic abnormalities associated with clinical variety of gastrointestinal stromal tumor
  Kazuto Nishio, Kinki University
Biomarkers for prediction of GI cancer treatment
  Daiki Miki, Hiroshima University / RIKEN
Genome-wide association study of hepatocellular carcinoma
  Koji Ueda, RIKEN
Development of pancreatic cancer biomarkers by focused proteomic technologies
  Hitoshi Zembutsu, The University of Tokyo
Genome-wide association study of pancreatic cancer and hematological toxicities in patients receiving gemcitabine.
  Rishu Takimoto, Sapporo Medical University
Targeting Anticancer Drug Delivery to Pancreatic Cancer Cells Using A Novel Nanoparticle Approach
Collapse

4. Topics of breast cancer

Thursday, September 20, 2:00PM

Chairpersons: Yoshio Miki, Tokyo Medical and Dental University
  Shunsuke Haga, Nippon Medical School
Speakers: Yoshio Miki, Tokyo Medical and Dental University
Hereditary breast/ovarian cancer -New development of the molecular diagnosis and treatment-
  Seigo Nakamura, Showa University Hospital
Current status and future perspectives for hereditary breast and ovarian cancer in Japan
  Hisataka Sabe, Hokkaido University
RTKs-GEP100-Arf6-AMAP1 pathway mediates cancerous EMT in response to mutant p53 and TGFbeta1 signaling
  Shigehira Saji, Kyoto University
Current treatment strategy to advanced or metastatic breast cancer
  Toyomasa Katagiri, The University of Tokushima
New insight into developing treatment strategies for breast cancer
  Yutaka Tokuda, Tokai University
Molecular-targeted therapy for breast cancer
Collapse

5. Molecular pathobiology of urologic neoplasm

Friday, September 21, 9:00AM

Chairpersons: Taiji Tsukamoto, Sapporo Medical University
  Taizo Shiraishi, Mie University
Speakers: Hiroshi Kitamura, Sapporo Medical University
Biomarkers for prognosis and treatment selection in kidney and bladder cancer patients
  Yoji Nagashima Yokohama City University
Pathology of renal neoplasms toward the era of molecular target therapy.
  Keiji Shimada, Nara Medical University
Molecular biological and pathological factors for urothelial carcinoma progression
  Akira Yokomizo, Kyushu University
The significance of clinicopathological factors associated with prognosis and therapeutic modalities in prostate cancer
  Yoshifumi Hirokawa, Mie University
Effects of TGFb1 treated prostate cancer cell on tumor microenvironment and pathological examination of prostate cancer
Collapse

6. Topics of bone and soft part sarcoma

Friday, September 21, 2:00PM

Chairpersons: Takuro Wada, Sapporo Medical University
  Yoshinao Oda, Kyushu University
Speakers: Masanori Hisaoka University of Occupational and Environmental Health
Molecular Pathology and Genetics in Soft Tissue Sarcomas
  Miwa Tanaka, The Cancer Institute, Japanese Foundation for Cancer Research
Tumorigenic mechanisms of gene fusion-related sarcoma: study using animal models
  Yoshinao Oda, Kyushu University
Investigation of the molecular target in soft tissue sarcoma
  Junya Toguchida, Kyoto University
Application of stem cell research for the investigation of sarcoma pathology
  Akira Kawai, National Cancer Center Hospital
Molecular markers of bone and soft tissue sarcomas revealed by proteomics
  Tomohide Tsukahara, Sapporo Medical University
Peptide vaccination therapy for patients with bone and soft tissue sarcoma
Collapse

Lecture Symposium for Oncology Pharmacists

Lecture Symposium for Oncology Pharmacists

Wednesday, September 19, 2:00PM

Chairpersons: Atsushi Miyamoto, Sapporo Medical University Hospital
  Toshihiro Hama, The Cancer Institute Hospital of JFCR
Speakers: Katsuyuki Nakamura, Sapporo Medical University Hospital
Contribution for safe and high quality cancer chemotherapy
  Maki Nemoto, The Cancer Institute Hospital
Total management for cancer therapy by the Oncology Pharmacy Specialist
  Hisanaga Nomura, Kyorin Univeristy Hospital
Finding solution to clinical question: Tips and Tools for Oncology Pharmacists.
  Yuki Kumihashi, Tokushima Red Cross Hospital
Management of adverse reactions with regional community for cancer patients
  Makio Imamura, Kurashiki Medical Center
A Challenge for Training Next-Generation Oncology Pharmacy Specialists.
Collapse

Morning Lecture

1. Resistance and residual disease following molecular-targeted therapy in cancer

Thursday, September 20, 8:00 AM - 8:45 AM

Chairperson: Kimitoshi Kohno, University of Occupational and Environmental Health
Speaker: Tomoki Naoe, Nagoya University
Collapse

2. Heat shock response and cancer

Thursday, September 20, 8:00 AM - 8:45 AM

Chairperson: Shinya Toyokuni, Nagoya University
Speaker: Akira Nakai, Yamaguchi University
Collapse

3. Cancer Metabolomics

Thursday, September 20, 8:00 AM - 8:45 AM

Chairperson: Hirotoshi Akita, Hokkaido University
Speaker: Tomoyoshi Soga, Keio University
Collapse

4. Tumor immunity: Regulation by innate and acquired immunity

Thursday, September 20, 8:00 AM - 8:45 AM

Chairperson: Hiroki Yamaue, Wakayama Medical University
Speaker: Toshinori Nakayama, Chiba University
Collapse

5. How to write and submit English manuscripts

Thursday, September 20, 8:00 AM - 8:45 AM

Chairperson: Hideyuki Saya, Keio University
Speaker: Hiroyuki Mano, Jichi Medical University / The University of Tokyo
Collapse

6. Advanced radiotherapy and cancer research up-to-date

Thursday, September 20, 8:00 AM - 8:45 AM

Chairperson: Nagara Tamaki, Hokkaido University
Speaker: Hiroki Shirato, Hokkaido University
Collapse

7. Update on intratumoral hormone production in breast cancer

Thursday, September 20, 8:00 AM - 8:45 AM

Chairperson: Hitoshi Tsuda, National Cancer Center Hospital
Speaker: Hironobu Sasano, Tohoku University
Collapse

8. Role of nutrient sensing signaling pathways in the stemness of cancer cells

Thursday, September 20, 8:00 AM - 8:45 AM

Chairperson: Masaki Yasukawa, Ehime University
Speaker: Atsushi Hirao, Kanazawa University
Collapse

9. Unknown origin cancer and spontaneous regression

Thursday, September 20, 8:00 AM - 8:45 AM

Chairperson: Shingo Ichimiya, Sapporo Medical University
Speaker: Akira Nakagawara, Chiba Cancer Center
Collapse

10. Milestone and future of gastric cancer research

Thursday, September 20, 8:00 AM - 8:45 AM

Chairperson: Okio Hino, Juntendo University
Speaker: Wataru Yasui, Hiroshima University
Collapse

11. Uncovering drug response and diversity of cancer as system by supercomputer

Thursday, September 20, 8:00 AM - 8:45 AM

Chairperson: Hidetoshi Tahara, Hiroshima University
Speaker: Satoru Miyano, The University of Tokyo
Collapse

12. The role of matricellular proteins and their integrin receptors in generation of tumor tissue microenvironments

Thursday, September 20, 8:00 AM - 8:45 AM

Chairperson: Hiroyasu Esumi, National Cancer Center Research Institute
Speaker: Toshimitsu Uede, Hokkaido University
Collapse

13. Clinical significance of circulating tumor cells

Friday, September 21, 8:00 AM - 8:45 AM

Chairperson: Yoshihiko Maehara, Kyushu University
Speaker: Masaki Mori, Osaka University
Collapse

14. Liver cancer stem cell and stress response

Friday, September 21, 8:00 AM - 8:45 AM

Chairperson: Toshiya Kamiyama, Hokkaido University
Speaker: Katsuhiko Enomoto, Akita University
Collapse

15. Innate immune signaling and cancer

Friday, September 21, 8:00 AM - 8:45 AM

Chairperson: Jun-ichiro Inoue, The University of Tokyo
Speaker: Akinori Takaoka, Hokkaido University
Collapse

16. Understanding the immunopathology of tumor microenvironment and its clinical applications

Friday, September 21, 8:00 AM - 8:45 AM

Chairperson: Masaaki Oka, Yamaguchi University
Speaker: Yutaka Kawakami, Keio University
Collapse

17. Metabolism of tissue microenvironmental factors by metalloproteinases in cancer cell proliferation and progression

Friday, September 21, 8:00 AM - 8:45 AM

Chairperson: Motoharu Seiki, The University of Tokyo
Speaker: Yasunori Okada, Keio University
Collapse

18. Tight junction and cancer

Friday, September 21, 8:00 AM - 8:45 AM

Chairperson: Yuji Nishikawa, Asahikawa Medical University
Speaker: Norimasa Sawada, Sapporo Medical University
Collapse

19. Nano-scale detection of membrane lipids by electron microscopy

Friday, September 21, 8:00 AM - 8:45 AM

Chairperson: Haruhiko Sugimura, Hamamatsu Medical University
Speaker: Toyoshi Fujimoto, Nagoya University
Collapse

20. Therapeutic strategies targeting cancer stem cells

Friday, September 21, 8:00 AM - 8:45 AM

Chairperson: Junji Kato, Sapporo Medical University
Speaker: Toru Kondo, Hokkaido University
Collapse

21. Epigenetic regulation of the mammalian X chromosome

Friday, September 21, 8:00 AM - 8:45 AM

Chairperson: Masanori Kasahara, Hokkaido University
Speaker: Takashi Sado, Kyushu University
Collapse

22. New topics in the p53 tumor suppressor pathway

Friday, September 21, 8:00 AM - 8:45 AM

Chairperson: Masao Seto, Aichi Cancer Center
Speaker: Takashi Tokino, Sapporo Medical University
Collapse

23. Mechanisms of cell migration regulated by Akt and Wnt signaling pathways

Friday, September 21, 8:00 AM - 8:45 AM

Chairperson: Tetsu Akiyama, The University of Tokyo
Speaker: Masahide Takahashi, Nagoya University
Collapse

24. Regulatory mechanisms for the malignant properties of cancer cells by sugar chains

Friday, September 21, 8:00 AM - 8:45 AM

Chairperson: Tatsuro Irimura, The University of Tokyo
Speaker: Koichi Furukawa, Nagoya University
Collapse
  • Show Full Program
  • Collapse Program
  • JAPANESE
  • ENGLISH